ResultsIQ

ResultsIQ › Latest results › Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited Q2 FY27 results deck summary

NSE: AKUMS · BSE: 544222

Results deck of 2 Nov 2026, summarised by AI from the filing.

Q2 FY27 revenue rose 31.9% YoY to ₹1,342 cr and PAT 168.3% to ₹115 cr, led by CDMO volume growth.

Key takeaways

  1. No numeric guidance Management gave no numeric revenue or margin guidance, only that it remains optimistic of delivering positive results.
  2. Sequential growth Revenue rose 15.1% QoQ to ₹1,342 cr from ₹1,167 cr and EBITDA rose 11.5% QoQ to ₹195 cr from ₹175 cr.

Original filing on BSE

Akums Drugs and Pharmaceuticals Limited Q2 FY27 results

As filed: Revenue ₹1,342 cr (+32% year on year), EBITDA ₹195 cr (+105% year on year), PAT ₹115 cr (+166% year on year), EBITDA margin 14.5% (+517 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹1,167 cr (+14% year on year), EBITDA ₹175 cr (+35% year on year), PAT ₹101 cr (+55% year on year), EBITDA margin 15.0% (+238 bps). Score 69 of 100, Above trend. Revenue and profit growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin rose 238 bps year on year. Consolidated profit +55% but standalone 0%. Share price after the results: +8.2% in 30 days (Nifty 500: −2.3%).
  • Q4 FY26: Revenue ₹1,158 cr (+10% year on year), EBITDA ₹152 cr (+61% year on year), PAT ₹81.3 cr (−46% year on year), EBITDA margin 13.1% (+420 bps). Score 49 of 100, In line with trend. EBITDA margin rose 420 bps year on year. Other income 29% of PBT. Not enough history for a trend yet: scored on growth alone. Share price after the results: +15.3% in 29 days (Nifty 500: +1.0%).
  • Q3 FY26: Revenue ₹1,160 cr (+15% year on year), EBITDA ₹147 cr (+21% year on year), PAT ₹67.7 cr (+37% year on year), EBITDA margin 12.7% (+68 bps). Score 53 of 100, In line with trend. EBITDA margin rose 68 bps year on year. Other income 34% of PBT. Consolidated profit +3% but standalone -31%. Not enough history for a trend yet: scored on growth alone. Share price after the results: +4.2% in 28 days (Nifty 500: −8.2%).
  • Q2 FY26: Revenue ₹1,018 cr (−1% year on year), EBITDA ₹95.0 cr (−22% year on year), PAT ₹43.0 cr (−36% year on year), EBITDA margin 9.3% (−248 bps). Score 7 of 100, Below trend. EBITDA margin fell 248 bps year on year. Other income 48% of PBT. Not enough history for a trend yet: scored on growth alone. Profit fell 34% from last quarter. Share price after the results: −3.3% in 29 days (Nifty 500: −0.4%).
  • Q1 FY26: Revenue ₹1,024 cr (0% year on year), EBITDA ₹129 cr (+2% year on year), PAT ₹65.0 cr (+7% year on year), EBITDA margin 12.6% (+13 bps). Score 28 of 100, Below trend. EBITDA margin rose 13 bps year on year. Other income 28% of PBT. Not enough history for a trend yet: scored on growth alone. Revenue fell 3% from last quarter. Share price after the results: −4.2% in 28 days (Nifty 500: +1.7%).
  • Q4 FY25: Revenue ₹1,056 cr, EBITDA ₹94.0 cr, PAT ₹150 cr, EBITDA margin 8.9%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹1,056 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −1.1% in 30 days (Nifty 500: +1.7%).
  • Q3 FY25: Revenue ₹1,010 cr, EBITDA ₹121 cr, PAT ₹66.0 cr, EBITDA margin 12.0%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹1,010 cr). Scored once a year-earlier consolidated quarter exists.

Past price moves after results do not indicate future moves. Not a recommendation.

Akums Drugs and Pharmaceuticals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.